FM19G11 favors spinal cord injury regeneration and stem cell self-renewal by mitochondrial uncoupling and glucose metabolism induction

Stem Cells. 2012 Oct;30(10):2221-33. doi: 10.1002/stem.1189.

Abstract

Spinal cord injury is a major cause of paralysis with no currently effective therapies. Induction of self-renewal and proliferation of endogenous regenerative machinery with noninvasive and nontoxic therapies could constitute a real hope and an alternative to cell transplantation for spinal cord injury patients. We previously showed that FM19G11 promotes differentiation of adult spinal cord-derived ependymal stem cells under hypoxia. Interestingly, FM19G11 induces self-renewal of these ependymal stem cells grown under normoxia. The analysis of the mechanism of action revealed an early increment of mitochondrial uncoupling protein 1 and 2 with an early drop of ATP, followed by a subsequent compensatory recovery with activated mitochondrial metabolism and the induction of glucose uptake by upregulation of the glucose transporter GLUT-4. Here we show that phosphorylation of AKT and AMP-activated kinase (AMPK) is involved in FM19G11-dependent activation of GLUT-4, glucose influx, and consequently in stem cell self-renewal. Small interfering RNA of uncoupling protein 1/2, GLUT-4 and pharmacological inhibitors of AKT, mTOR and AMPK signaling blocked the FM19G11-dependent induction of the self-renewal-related markers Sox2, Oct4, and Notch1. Importantly, FM19G11-treated animals showed accelerated locomotor recovery. In vivo intrathecal sustained administration of FM19G11 in rats after spinal cord injury showed more neurofilament TUJ1-positive fibers crossing the injured area surrounded by an increase of neural precursor Vimentin-positive cells. Overall, FM19G11 exerts an important influence on the self-renewal of ependymal stem progenitor cells with a plausible neuroprotective role, providing functional benefits for spinal cord injury treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Adenylate Kinase / antagonists & inhibitors
  • Adenylate Kinase / genetics
  • Adult Stem Cells / drug effects*
  • Adult Stem Cells / metabolism
  • Adult Stem Cells / pathology
  • Animals
  • Benzamides / pharmacology*
  • Ependyma / drug effects
  • Ependyma / metabolism
  • Ependyma / pathology
  • Female
  • Gene Expression Regulation
  • Glucose / metabolism*
  • Glucose Transporter Type 4 / antagonists & inhibitors
  • Glucose Transporter Type 4 / genetics
  • Ion Channels / antagonists & inhibitors
  • Ion Channels / genetics
  • Mitochondria / metabolism*
  • Mitochondrial Proteins / antagonists & inhibitors
  • Mitochondrial Proteins / genetics
  • Nerve Regeneration / drug effects*
  • Neuroprotective Agents / pharmacology*
  • Oncogene Protein v-akt / antagonists & inhibitors
  • Oncogene Protein v-akt / genetics
  • RNA, Small Interfering / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction
  • Spinal Cord / drug effects
  • Spinal Cord / metabolism
  • Spinal Cord / pathology
  • Spinal Cord Injuries / pathology
  • Spinal Cord Injuries / therapy*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / genetics
  • Uncoupling Protein 1
  • Uncoupling Protein 2

Substances

  • Benzamides
  • FM19G11
  • Glucose Transporter Type 4
  • Ion Channels
  • Mitochondrial Proteins
  • Neuroprotective Agents
  • RNA, Small Interfering
  • Ucp1 protein, rat
  • Uncoupling Protein 1
  • Uncoupling Protein 2
  • Adenosine Triphosphate
  • Oncogene Protein v-akt
  • TOR Serine-Threonine Kinases
  • Adenylate Kinase
  • Glucose